TABLE 2.

Primary end-point: time to sustained clinical response

	Overall		Period 2 only#
	Tozorakimab+SoC (n=53)	SoC (n=44)	Tozorakimab+SoC (n=49)	SoC (n=32)
Patients with a sustained clinical response	42 (79.2)	32 (72.7)	39 (79.6)	22 (68.8)
Censored	11 (20.8)	12 (27.3)	10 (20.4)	10 (31.3)
Time to response, days	8.0 (5.0–22.0)	9.5 (4.0–NE)	8.0 (5.0–22.0)	8.5 (54.5–NE)
HR (80% CI); p-value	0.96 (0.70–1.31); 0.33		1.09 (0.77–1.54)

Data are presented as n (%) or median (interquartile range), unless otherwise stated. SoC: standard of care; NE: not estimable. ^#: data for period 1 were not analysed separately owing to the very small proportion of patients recruited in period 1.